Reductive silylation of Cp*UO2((Mes)PDI(Me)) promoted by Lewis bases

Functionalization of the uranyl moiety (UO2(2+)) in Cp*UO2((Mes)PDI(Me)) (1-PDI) ((Mes)PDI(Me) = 2,6-((Mes)N=CMe)2C5H3N; Mes = 2,4,6-triphenylmethyl), which bears a reduced, monoanionic pyridine(diimine) ligand, is reported. Silylating reagents, R3Si-X (R = Me, X = Cl, I, OTf, SPh; R = Ph, X = Cl), effectively add across the strong O=U=O bonds in the presence of the Lewis base, OPPh3, generating products of the form (R3SiO)2UX2(OPPh3)2 (R = Me, X = I (2-OPPh3), Cl (3-OPPh3), SPh (5-OPPh3), OTf (6-OPPh3); R = Ph, X = Cl (4-OPPh3)). During this transformation, reduction to uranium(iv) occurs with loss of (Cp*)2 and (Mes)PDI(Me), each of which acts as a one-electron source. In the reaction, the Lewis base serves to activate the silyl halide, generating a more electrophilic silyl group, as determined by (29)Si NMR spectroscopy, that undergoes facile transfer to the oxo groups. Complete U-O bond scission was accomplished by treating the uranium(iv) disiloxide compounds with additional silylating reagent, forming the family (Ph3PO)2UX4. All compounds were characterized by (1)H NMR, infrared, and electronic absorption spectroscopies. X-ray crystallographic characterization was used to elucidate the structures of 2-OPPh3, 4-OPPh3, 5-OPPh3, and 6-OPPh3.

Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation

Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) is a serious complication of organ and bone marrow transplantation. The importance of EBV matching between recipient and donor remains unclear. Between October 1987 and December 1997, 64 pediatric cardio-pulmonary transplants were performed at this center (58 hearts, two heart/lungs, four sequential single lungs). The EBV viral capsid antigen (VCA) immunoglobulin G (IgG) status of both donor and recipient was determined at the time of transplant. Of 56 patients from whom paired sera was available for analysis, 27 (50%) were recipient and donor EBV IgG positive, four (7%) were recipient EBV IgG positive and donor EBV IgG negative, and 12 (20%) were recipient EBV IgG negative and donor EBV IgG negative. The remaining 13 (23%) patients were EBV IgG negative but received organs from EBV IgG-positive donors. The EBV immunoglobulin M (IgM) status was determined from 6 weeks post-transplant in the 11 mismatches who survived for longer than 28 d. Seven became EBV IgM positive, two remained EBV IgM negative; the status of the remaining two remains unknown. The EBV IgM status was also determined retrospectively in patients who were EBV IgG negative pretransplant and received organs from EBV IgG-negative donors. Nine became EBV IgM positive; the rest remained negative. PTLD was diagnosed in two of 56 patients from whom paired sera was available; one was donor and recipient EBV IgG negative; the other was donor and recipient EBV IgG positive. No cases of PTLD were diagnosed in the remaining eight patients from whom paired sera was not available. Our experience suggests that PTLD does not occur with any greater frequency in the 'mismatch' group, and does not justify EBV matching in pediatric thoracic transplantation where there is a higher proportion of EBV-negative recipients than in adults.

Lycaconitine revisited: partial synthesis and neuronal nicotinic acetylcholine receptor affinities

The norditerpenoid alkaloid lycaconitine (2) was synthesized from lycoctonine (3) and its affinity determined for two neuronal nicotinic acetylcholine receptor subtypes. The structure of 2 was confirmed by a combination of spectroscopic methods.

Isocladosporin, a biologically active isomer of cladosporin from Cladosporium cladosporioides

Extraction of the fungus Cladosporium cladosporioides yielded the known isocoumarin, cladosporin [1], and a new compound. This metabolite, which inhibited the growth of etiolated wheat coleoptiles slightly more than did cladosporin, was characterized as a diastereoisomer of cladosporin at C-14 and was named isocladosporin [2].

Identification of phosphocholine plasmalogen as a lipid component in mammalian pulmonary surfactant using high-resolution 31P NMR spectroscopy

High-resolution 31P NMR spectroscopy was used to analyze the phospholipid composition of mammalian pulmonary surfactant from two different sources. Under conditions which considerably narrow the usually broad 31P phospholipid signals, solution-phase NMR spectra of these surfactant preparations unequivocally demonstrate that a phosphocholine plasmalogen (i.e., 1-O-(1'-alkenyl)-2-acyl-sn-glycero-3-phosphocholine) exists as a major secondary component (approximately 4 mol%) in mammalian pulmonary surfactant. Phosphocholine (PC) plasmalogen was identified in preparations obtained from both adult cow lung surfactant extract as well as in ovine (lamb) fetal pulmonary liquid. PC plasmalogens have not previously been identified any mammalian pulmonary surfactant preparation. The amount of PC plasmalogen in these preparations occurs at fractional levels that are comparable to that of phosphoglycerol (PG), which previously had been thought of as the second-most common phospholipid class in pulmonary surfactant. The presence of PC plasmalogen in pulmonary surfactant may have important physiological ramifications and immediately suggests new directions for biochemical and biophysical investigations of pulmonary surfactant.